APA (7th ed.) Citation

Ambery, C. L., Wielders, P., Ludwig-Sengpiel, A., Chan, R., & Riley, J. H. (2015). Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β2-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial. Drugs in R&D, 15(3), 281. https://doi.org/10.1007/s40268-015-0104-x

Chicago Style (17th ed.) Citation

Ambery, Claire L., Pascal Wielders, Andrea Ludwig-Sengpiel, Robert Chan, and John H. Riley. "Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β2-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial." Drugs in R&D 15, no. 3 (2015): 281. https://doi.org/10.1007/s40268-015-0104-x.

MLA (9th ed.) Citation

Ambery, Claire L., et al. "Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β2-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial." Drugs in R&D, vol. 15, no. 3, 2015, p. 281, https://doi.org/10.1007/s40268-015-0104-x.